Accelerated/Blast-phase Myeloproliferative Neoplasm (1)

Chronic-phase Myelofibrosis (1)

IDH2 Mutation (1)

Recruiting (1)

phase 2 (1)

John Mascarenhas (1)

Celgene Corporation (1)

Incyte Corporation (1)

Myeloproliferative Neoplasms Research Consortium (1)

National Cancer Institute (NCI) (1)

National Institutes of Health (NIH) (1)

enasidenib (1)

ruxolitinib (1)

drug (1)

Other (1)

Interventional (1)

idh2 mutation

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Recruiting

May 9, 2022